Tharimmune presents positive clinical data highlighting th104 metabolic profile and advances program for prophylaxis against ultrapotent opioid exposure following fda feedback

Bridgewater, new jersey / access newswire / may 6, 2025 / tharimmune, inc., (nasdaq:thar) ("tharimmune" or the "company") a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology released pharmacokinetic and metabolism data from its phase 1 study of th104, a buccal film formulation of nalmefene, in healthy subjects. tharimmune recently highlighted the advancement of th104 for the proposed indication of temporary prophylaxis against respiratory and/or central nervous system depression in military personnel and chemical incident responders exposed to high-potency opioids, following recent positive feedback from the u.s. food and drug administration (fda).
THAR Ratings Summary
THAR Quant Ranking